Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy

Angela Zimmerman, Paula R. Clemens, Carolina Tesi-Rocha, Anne Connolly, Susan T. Iannaccone, Nancy Kuntz, Adrienne Arrieta, Lauren Hache, Erik Henricson, Fengming Hu, Jill Mayhew, Diana M. Escolar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: In this study we performed an open-label, pilot study of an orally administered liquid formulation of immediate-release pentoxifylline (PTX) on patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety, and tolerability were assessed. Methods: The tolerability and safety of PTX and measures of muscle strength and function were evaluated during 12 months of treatment. Results: Seventeen boys with DMD, between 4 and 8 years of age, were enrolled at one of five Cooperative International Neuromuscular Research Group (CINRG) centers. Only 9 were able to complete the 12-month PTX treatment phase; the primary reason for discontinuation was adverse events. Intolerable gastrointestinal side effects were experienced by 65% of participants. Two participants had severe leukopenia that resolved with medication withdrawal. Conclusions: Open-label treatment with a liquid formulation of immediate-release PTX resulted in a high incidence of adverse events in boys with DMD. Poor tolerability of this PTX formulation precluded adequate assessment of efficacy.

Original languageEnglish (US)
Pages (from-to)170-173
Number of pages4
JournalMuscle and Nerve
Volume44
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Pentoxifylline
Duchenne Muscular Dystrophy
Therapeutics
Safety
Leukopenia
Muscle Strength
Incidence
Research

Keywords

  • Clinical trial
  • Duchenne
  • Leukopenia
  • Muscular dystrophy
  • Pentoxifylline

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Zimmerman, A., Clemens, P. R., Tesi-Rocha, C., Connolly, A., Iannaccone, S. T., Kuntz, N., ... Escolar, D. M. (2011). Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy. Muscle and Nerve, 44(2), 170-173. https://doi.org/10.1002/mus.22127

Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy. / Zimmerman, Angela; Clemens, Paula R.; Tesi-Rocha, Carolina; Connolly, Anne; Iannaccone, Susan T.; Kuntz, Nancy; Arrieta, Adrienne; Hache, Lauren; Henricson, Erik; Hu, Fengming; Mayhew, Jill; Escolar, Diana M.

In: Muscle and Nerve, Vol. 44, No. 2, 08.2011, p. 170-173.

Research output: Contribution to journalArticle

Zimmerman, A, Clemens, PR, Tesi-Rocha, C, Connolly, A, Iannaccone, ST, Kuntz, N, Arrieta, A, Hache, L, Henricson, E, Hu, F, Mayhew, J & Escolar, DM 2011, 'Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy', Muscle and Nerve, vol. 44, no. 2, pp. 170-173. https://doi.org/10.1002/mus.22127
Zimmerman, Angela ; Clemens, Paula R. ; Tesi-Rocha, Carolina ; Connolly, Anne ; Iannaccone, Susan T. ; Kuntz, Nancy ; Arrieta, Adrienne ; Hache, Lauren ; Henricson, Erik ; Hu, Fengming ; Mayhew, Jill ; Escolar, Diana M. / Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy. In: Muscle and Nerve. 2011 ; Vol. 44, No. 2. pp. 170-173.
@article{98179653c5584e1682031cee168c3a52,
title = "Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy",
abstract = "Introduction: In this study we performed an open-label, pilot study of an orally administered liquid formulation of immediate-release pentoxifylline (PTX) on patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety, and tolerability were assessed. Methods: The tolerability and safety of PTX and measures of muscle strength and function were evaluated during 12 months of treatment. Results: Seventeen boys with DMD, between 4 and 8 years of age, were enrolled at one of five Cooperative International Neuromuscular Research Group (CINRG) centers. Only 9 were able to complete the 12-month PTX treatment phase; the primary reason for discontinuation was adverse events. Intolerable gastrointestinal side effects were experienced by 65{\%} of participants. Two participants had severe leukopenia that resolved with medication withdrawal. Conclusions: Open-label treatment with a liquid formulation of immediate-release PTX resulted in a high incidence of adverse events in boys with DMD. Poor tolerability of this PTX formulation precluded adequate assessment of efficacy.",
keywords = "Clinical trial, Duchenne, Leukopenia, Muscular dystrophy, Pentoxifylline",
author = "Angela Zimmerman and Clemens, {Paula R.} and Carolina Tesi-Rocha and Anne Connolly and Iannaccone, {Susan T.} and Nancy Kuntz and Adrienne Arrieta and Lauren Hache and Erik Henricson and Fengming Hu and Jill Mayhew and Escolar, {Diana M.}",
year = "2011",
month = "8",
doi = "10.1002/mus.22127",
language = "English (US)",
volume = "44",
pages = "170--173",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy

AU - Zimmerman, Angela

AU - Clemens, Paula R.

AU - Tesi-Rocha, Carolina

AU - Connolly, Anne

AU - Iannaccone, Susan T.

AU - Kuntz, Nancy

AU - Arrieta, Adrienne

AU - Hache, Lauren

AU - Henricson, Erik

AU - Hu, Fengming

AU - Mayhew, Jill

AU - Escolar, Diana M.

PY - 2011/8

Y1 - 2011/8

N2 - Introduction: In this study we performed an open-label, pilot study of an orally administered liquid formulation of immediate-release pentoxifylline (PTX) on patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety, and tolerability were assessed. Methods: The tolerability and safety of PTX and measures of muscle strength and function were evaluated during 12 months of treatment. Results: Seventeen boys with DMD, between 4 and 8 years of age, were enrolled at one of five Cooperative International Neuromuscular Research Group (CINRG) centers. Only 9 were able to complete the 12-month PTX treatment phase; the primary reason for discontinuation was adverse events. Intolerable gastrointestinal side effects were experienced by 65% of participants. Two participants had severe leukopenia that resolved with medication withdrawal. Conclusions: Open-label treatment with a liquid formulation of immediate-release PTX resulted in a high incidence of adverse events in boys with DMD. Poor tolerability of this PTX formulation precluded adequate assessment of efficacy.

AB - Introduction: In this study we performed an open-label, pilot study of an orally administered liquid formulation of immediate-release pentoxifylline (PTX) on patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety, and tolerability were assessed. Methods: The tolerability and safety of PTX and measures of muscle strength and function were evaluated during 12 months of treatment. Results: Seventeen boys with DMD, between 4 and 8 years of age, were enrolled at one of five Cooperative International Neuromuscular Research Group (CINRG) centers. Only 9 were able to complete the 12-month PTX treatment phase; the primary reason for discontinuation was adverse events. Intolerable gastrointestinal side effects were experienced by 65% of participants. Two participants had severe leukopenia that resolved with medication withdrawal. Conclusions: Open-label treatment with a liquid formulation of immediate-release PTX resulted in a high incidence of adverse events in boys with DMD. Poor tolerability of this PTX formulation precluded adequate assessment of efficacy.

KW - Clinical trial

KW - Duchenne

KW - Leukopenia

KW - Muscular dystrophy

KW - Pentoxifylline

UR - http://www.scopus.com/inward/record.url?scp=79960518961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960518961&partnerID=8YFLogxK

U2 - 10.1002/mus.22127

DO - 10.1002/mus.22127

M3 - Article

VL - 44

SP - 170

EP - 173

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 2

ER -